Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
2,937,388
-
Share change
-
-649,284
-
Total reported value
-
$6,146,180
-
Put/Call ratio
-
20%
-
Price per share
-
$2.10
-
Number of holders
-
34
-
Value change
-
+$407,625
-
Number of buys
-
17
-
Number of sells
-
10
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2023
As of 31 Mar 2023,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,937,388 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, MEITAV INVESTMENT HOUSE LTD, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, Connor, Clark & Lunn Investment Management Ltd., MARSHALL WACE, LLP, BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock Inc., MILLENNIUM MANAGEMENT LLC, and MORGAN STANLEY.
This page lists
34
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.